Last reviewed · How we verify
Clobetasol propionate foam
Clobetasol propionate is a potent topical corticosteroid that suppresses inflammatory and immune responses in the skin by binding to glucocorticoid receptors.
Clobetasol propionate is a potent topical corticosteroid that suppresses inflammatory and immune responses in the skin by binding to glucocorticoid receptors. Used for Inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses (scalp and body), Psoriasis, Lichen planus.
At a glance
| Generic name | Clobetasol propionate foam |
|---|---|
| Also known as | Olux-E |
| Sponsor | Stiefel, a GSK Company |
| Drug class | Topical corticosteroid (Class I, super-potent) |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | FDA-approved |
Mechanism of action
Clobetasol propionate is a Class I (super-potent) corticosteroid that works by activating intracellular glucocorticoid receptors, leading to decreased production of inflammatory mediators, reduced immune cell infiltration, and suppression of local inflammatory responses. The foam formulation provides enhanced penetration and coverage for scalp and other affected areas. It is used to rapidly reduce inflammation, itching, and other dermatological symptoms in various skin conditions.
Approved indications
- Inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses (scalp and body)
- Psoriasis
- Lichen planus
- Atopic dermatitis
Common side effects
- Skin atrophy
- Telangiectasia
- Striae
- Folliculitis
- Hypertrichosis
- Acneiform eruptions
- Hypopigmentation
Key clinical trials
- Treatment Results for Patients With Central Centrifugal Cicatricial Alopecia (CCCA): a Multicenter Prospective Study (PHASE4)
- A Comparison Between Clobetasol Propionate 0.05% (Clobex®) Spray and Clobetasol Propionate 0.05% (Olux®) Foam (PHASE4)
- Randomized Study to Compare the Bioavailability of Two Clobetasol Propionate 0.05% Topical Foams
- Subject Preference for Scalp Psoriasis Treatment (PHASE3)
- Treatment of Staphylococcus Aureus Colonization in Hand Eczema (NA)
- Role of Topical Treatments in the Modulation of Skin Microbiome in Psoriatic Skin (PHASE2)
- Evaluate Efficacy, and Safety of Topical Therapy and Etanercept in Subjects With Moderate to Severe Plaque Psoriasis (PHASE3)
- Ethanol-Free Clobetasol Propionate Foam 0.05% (Olux-E Foam) vs Vehicle Foam in the Treatment of Chronic Hand Dermatitis. (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Clobetasol propionate foam CI brief — competitive landscape report
- Clobetasol propionate foam updates RSS · CI watch RSS
- Stiefel, a GSK Company portfolio CI